NCT06358430View on ClinicalTrials.gov

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

PHASE1RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

January 18, 2029

Study Completion Date

January 18, 2029

Conditions
Colorectal CancerMinimal Residual Disease
Interventions
DRUG

Fludarabine Phosphate

Given by IV

DRUG

Cyclophosphamide

Given by IV

DRUG

Cetuximab

Given by IV

DRUG

TROP2-CAR-NK Cells

Given by IV

DRUG

Rimiducid (AP1903)

Given by IV

PROCEDURE

Lymphodepleting Chemotherapy

Given by Chemotherapy

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Bellicum Pharmaceuticals, Inc.

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER

NCT06358430 - Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) | Biotech Hunter | Biotech Hunter